Antoinette R. Tan, MD, MHSc, FACP is the Chief of Breast Medical Oncology and Co-Director of the Phase I Program at Levine Cancer Institute, Carolinas HealthCare System. She is Section Chief of Hematology/Oncology at Carolinas HealthCare System Pineville and is also a Clinical Professor in the Department of Medicine at the University of North Carolina. Prior to joining Levine Cancer Institute, Dr. Tan was an Associate Professor of Medicine and the Director of Phase I and Investigational Therapeutics at Rutgers Cancer Institute of New Jersey. Dr. Tan's focus is on the clinical development of targeted treatments for triple-negative breast cancer. She has extensive experience in the conduct of early-phase clinical trials and breast cancer studies and has been the recipient of an NCI Cancer Clinical Investigator Team Leadership Award. She has been Principal Investigator for several trials focusing on the treatment of triple-negative breast cancer. Dr. Tan has served on the American Society of Clinical Oncology Education Program, as Chair and as a Breast Cancer Track Leader. She has also been actively involved in the clinical development of novel therapeutics, with leadership roles in the National Surgical Adjuvant Breast and Bowel Project (NSABP) and NRG Oncology. She has published many scientific papers and book chapters, and has served as a book editor.

Provides a comprehensive summary of multidisciplinary management of triple-negative breast cancer

Offers a thorough clinical review of the issues faced in real-world practice

Features practical advice from the experts

Includes supplementary material: [...]

1. Pathologic evaluation of triple-negative breast cancer.- 2. Triple-negative breast cancer: Clinical features.- 3. The genetics of triple-negative breast cancer.- 4. Imaging features and modalities of triple-negative breast cancer.- 5. Surgical management of triple-negative breast cancer.- 6. Radiation therapy for triple-negative breast cancer.- 7. Tailoring adjuvant therapy for triple-negative breast cancer: Selection of agents.- 8. Neoadjuvant treatment of triple-negative breast cancer.- 9. Systemic treatment of metastatic triple-negative breast cancer Page 3 of 3.- 10. Molecular profiling and targeted therapy for triple-negative breast cancer.- 11. Special issues in the young woman with triple-negative breast cancer.- 12. Individualizing the approach to the older woman with triple-negative breast Cancer.